View on Pubmed.gov 40345488 | View on doi.org 10.1016/j.ando.... (full text)
ENDOCAN TUTHYREF network consensus recommendations: Refractory follicular-derived thyroid cancer.
- Department of Endocrinology, CHRU de Lille-Hôpital Claude Huriez, Lille, France. Electronic address: christine.docao@chu-lille.fr.
- Department of Thyroid Oncology and Nuclear Medicine, Institut Bergonié, Bordeaux, France.
- Department of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, Caen, France.
- Department of Endocrinology, Hôpital Louis Pradel, Hospices Civils de Lyon, Lyon, France.
- Pathology department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.
- Medical Oncology Department, Pitié-Salpêtrière Hospital, Paris, France.
- Department of Medical Oncology, CHU de Nantes-Hôpital Laennec Saint-Herblain, Nantes, France.
- Department of Nuclear Medicine, IUCT Oncopole Claudius Regaud, Toulouse, France.
- Department of Endocrinology and Diabetology, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
- Department of Medical Oncology, Tours University Hospital, Tours, France.
- Department of Endocrinology, CHRU de Lille-Hôpital Claude Huriez, Lille, France.
- Department of Medical Imaging, Endocrine Oncology Unit, Gustave Roussy, 94805 Villejuif, France.
- Department of Nuclear Medicine, Institut Curie, Saint-Cloud, France.
- Thyroid and Endocrine Tumors Department, Pitié-Salpêtrière Hospital, Thyroid Tumors Clinical Research Group, Sorbonne University, Cancer Institute, Paris, France.
ENDOCAN-TUTHYREF network
Abstract
Radioactive-iodine-refractory differentiated thyroid cancer (RAIR DTC) represents 3-5% of follicular-derived DTCs, with approximately 200-300 new cases diagnosed annually in France. Median overall survival in the French RAIR DTC database is 9.5years, underscoring the importance of long-term support for caregivers and patients. To guide treatment decision-making, the French ENDOCAN TUTHYREF network has provided algorithms for RAIR DTC management, available at the TUTHYREF website. The present article summarizes these recent practical recommendations, focusing on 5 points. (1) RAIR DTC has long been defined by locally advanced disease not amenable to surgery or metastatic disease not fully responding to radioactive iodine (RAI) therapy, a definition that can be further refined considering prognostic factors. (2) Treatment should be tailored according to tumor burden and progression, with local treatments prioritized for non-progressive or slowly progressive disease. (3) Early tumor molecular testing should be performed to identify driver oncogenes such as BRAF mutation or RET/NTRK/ALK fusion, to optimize access to existing selective targeted therapies. (4) For symptomatic or progressive RAIR DTC, tyrosine multikinase inhibitors, such as sorafenib, lenvatinib or cabozantinib, are the standard therapies, but alternative and 2nd-line kinase inhibitors are also available. (5) Since most therapies are associated with common side-effects such as fatigue and cardiovascular, digestive and skin issues, preparing and monitoring patients for systemic therapy should include careful assessment of comorbidities, toxicity prevention and individual dose adjustment. Overall, management of RAIR DTC requires a multidisciplinary approach, with an emphasis on personalized treatment strategies and proactive therapeutic education.
References
Cited by 4 citations (total)
Case Reports Journal Article
EML4::RET, a novel transcript fusion in papillary thyroid cancer.
Electronic publication date September 17, 2026
Renaud Ciappuccini [...] Stéphane Bardet et al.
Fusion genes are the most common genetic alterations found in pediatric papillary thyroid cancers (PTCs). Pediatric PTCs harboring fusion genes...
Conflict of interest statement
MeSH
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Substances
Copyright
Copyright © 2025 The Authors. Published by Elsevier Masson SAS.. All rights reserved.